News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Stop-start hormone therapy better than continual treatment for prostate cancer
Men with prostate cancer who receive hormone therapy intermittently respond as well as those who receive it over a continuous time period, and enjoy quality-of-life benefits, according to a study published in the New England Journal of Medicine today.
Golden age of prostate cancer treatment - fourth drug in two years extends life
A study in the New England Journal of Medicine shows the drug enzalutamide can significantly extend life and improve quality of life in men with advanced prostate cancer – the fourth time in two years that a new drug has been shown to improve overall survival.
The Institute of Cancer Research turns up the heat on tumour cells
Researchers at The Institute of Cancer Research (ICR) are investigating a new treatment that could destroy cancer cells in the abdomen by zapping them with intense soundwaves.
Lower risk of serious side-effects in trials of new targeted drugs
Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis.
New evidence found for inheritability of common leukaemia
Scientists at The Institute of Cancer Research (ICR) in London have identified a heritable gene variant associated with an increased risk of developing chronic lymphocytic leukaemia (CLL).
Obesity may affect response to breast cancer treatment
Women who are obese continue to have higher levels of oestrogen than women of normal weight even after treatment with hormone-suppressing drugs, raising the possibility that they might benefit from changes to their treatment.
Cancer treatment progress: Two promising new drugs revealed
Scientists at The Institute of Cancer Research have this week revealed promising early results from two exciting new targeted cancer drug
Drug’s ‘double hit’ overcomes leukaemia resistance
A drug that uses a unique ‘double hit’ to kill leukaemia cells could be a potential new treatment for patients with acute myeloid leukaemia. The research, led by the ICR, is published today in the journal Leukaemia.
Scientists develop new strategy to overcome drug-resistant childhood cancer
A new drug combination could offer hope to children with neuroblastoma – one of the deadliest forms of childhood cancer – by boosting the effectiveness of a promising new gene-targeted treatment.
'Master switch' experimental drug could treat different cancers
A unique multi-target experimental drug could treat a range of cancer types, according to research led by the ICR and published in Clinical Cancer Research today.
Pan-European project aims to screen patients for hidden cancer cells
Scientists across Europe are to collaborate on a €6m project to develop a technique of screening a patient’s entire blood volume for cancer cells that have evaded treatment.
Cancer drug discoverer honoured with global entrepreneurship award
Professor Paul Workman has won a global award recognising his success at taking pioneering drugs out of the laboratory and into commercial development for the ultimate benefit of patients worldwide.
